Literature DB >> 6275941

Confirmation of herpes simplex virus type 2 infections in herpes-like genital lesions by a simple complement-fixation test.

M Arsenakis, J T May.   

Abstract

The presence of complement-fixing antibody to an early herpes simplex virus type 2 (HSV-2) antigen (the AG-4 antigen) was correlated with HSV-2 infection in the sera of patients with genital herpes. Eighty-eight per cent of sera taken two weeks after clinical diagnosis of a primary or recurrent herpes infection in patients, confirmed to have HSV-2 by virus isolation and typing, contained the anti-AG-4 complement-fixing antibody. None of the patients with genital HSV-1 had the antibody, and only 9% of controls or patients with facial HSV-1 infection had positive results for the antibody. This correlation was used to identify genital HSV-2 infections when either no virus sample had been taken or when virus isolations had been unsuccessful. Thus, a simple complement-fixation test can confirm an HSV-2 virus infection without isolation of the virus from the herpetic lesion.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6275941      PMCID: PMC1046000          DOI: 10.1136/sti.58.1.48

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  12 in total

1.  Identification of strains of herpes simplex virus by comparison of the density of their DNA using the preparative ultracentrifuge.

Authors:  I W Halliburton; E A Hill; G J Russell
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

2.  Incidence and distribution of herpes simplex virus types 1 and 2 from genital lesions in college women.

Authors:  J E Kalinyak; G Fleagle; J J Docherty
Journal:  J Med Virol       Date:  1977       Impact factor: 2.327

3.  Detection of herpesvirus type-specific antibody by a micro solid phase radioimmunometric assay.

Authors:  G R Dreesman; D O Matson; R J Courtney; E Adam; J L Melnick
Journal:  Intervirology       Date:  1979       Impact factor: 1.763

4.  Clinical features of herpes genitalis.

Authors:  R H Kaufman; H L Gardner; W E Rawls; R E Dixon; R L Young
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

Review 5.  A review of the identification and titration of antibodies to herpes simplex viruses type 1 and type 2 in human sera.

Authors:  G Plummer
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

6.  Rapid typing of herpes simplex virus strains using the indirect immunoperoxidase method.

Authors:  D R Benjamin
Journal:  Appl Microbiol       Date:  1974-10

7.  Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells.

Authors:  P M Ejercito; E D Kieff; B Roizman
Journal:  J Gen Virol       Date:  1968-05       Impact factor: 3.891

8.  A rapid technique for distinguishing herpes-simplex virus type 1 from type 2 by restriction-enzyme technology.

Authors:  D M Lonsdale
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

9.  AG-4 complement-fixing antibodies in cervical cancer and herpes-infected patients using local herpes simplex virus type 2.

Authors:  M Arsenakis; G M Georgiou; J K Welsh; M N Cauchi; J T May
Journal:  Int J Cancer       Date:  1980-01-15       Impact factor: 7.396

10.  Antibody to HSV-2 induced tumor specific antigens in serums from patients with cervical carcinoma.

Authors:  L Aurelian; B Schumann; R L Marcus; H J Davis
Journal:  Science       Date:  1973-07-13       Impact factor: 47.728

View more
  3 in total

1.  Type specificity of complement-fixing antibody against herpes simplex virus type 2 AG-4 early antigen in patients with asymptomatic infection.

Authors:  C H Sherlock; R L Ashley; M L Shurtleff; K D Mack; L Corey
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

2.  Analysis of the HSV-2 early AG-4 antigen.

Authors:  L A Evans; M Sheppard; J T May
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

3.  Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.

Authors:  Joshua J Geltz; Edward Gershburg; William P Halford
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.